The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27816515 |
143 |
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.![EBI](/images/logo_chembl.png) |
Merck |
27089211 |
38 |
Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.![EBI](/images/logo_chembl.png) |
Zhejiang University |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).![EBI](/images/logo_chembl.png) |
Icahn School of Medicine At Mount Sinai |
26652860 |
68 |
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.![EBI](/images/logo_chembl.png) |
Korea Institute of Science & Technology (Kist) |
26071372 |
89 |
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.![EBI](/images/logo_chembl.png) |
Astellas Pharma |
23434140 |
35 |
Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.![EBI](/images/logo_chembl.png) |
East China University of Science and Technology |
23550937 |
72 |
Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.![EBI](/images/logo_chembl.png) |
Emory University |
23394126 |
170 |
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).![EBI](/images/logo_chembl.png) |
Exelixis |
23142618 |
66 |
Discovery of a novel series of 4-quinolone JNK inhibitors.![EBI](/images/logo_chembl.png) |
Roche Palo Alto |
23127890 |
96 |
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.![EBI](/images/logo_chembl.png) |
Exelixis |
22320327 |
250 |
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.![EBI](/images/logo_chembl.png) |
Amgen |
22521647 |
56 |
Conjugates of 5-isoquinolinesulfonylamides and oligo-D-arginine possess high affinity and selectivity towards Rho kinase (ROCK).![EBI](/images/logo_chembl.png) |
University of Tartu |
22450127 |
64 |
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.![EBI](/images/logo_chembl.png) |
Exelixis |
17850214 |
99 |
The selectivity of protein kinase inhibitors: a further update.![EBI](/images/logo_chembl.png) |
University of Dundee |
14593182 |
34 |
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.![EBI](/images/logo_chembl.png) |
Pfizer |
18077425 |
197 |
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.![EBI](/images/logo_chembl.png) |
Harvard Medical School |
18345609 |
57 |
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.![EBI](/images/logo_chembl.png) |
The Institute of Cancer Research |
17983756 |
55 |
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.![EBI](/images/logo_chembl.png) |
Osi Pharmaceuticals |
17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.![EBI](/images/logo_chembl.png) |
Abbott Laboratories |
17887663 |
34 |
Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors.![EBI](/images/logo_chembl.png) |
Pfizer |
22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).![EBI](/images/logo_chembl.png) |
Ansaris |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity.![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
21391610 |
139 |
Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
24900229 |
41 |
Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery.![EBI](/images/logo_chembl.png) |
TBA |
21185721 |
26 |
Potent and selective thiophene urea-templated inhibitors of S6K.![EBI](/images/logo_chembl.png) |
Pfizer |
19465931 |
12 |
Inhibitor hijacking of Akt activation.![EBI](/images/logo_chembl.png) |
University of California |
20684549 |
76 |
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.![EBI](/images/logo_chembl.png) |
Amgen |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
10998351 |
24 |
Specificity and mechanism of action of some commonly used protein kinase inhibitors.![EBI](/images/logo_chembl.png) |
University of Dundee |
20462263 |
127 |
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.![EBI](/images/logo_chembl.png) |
Cyclacel |
20074837 |
58 |
The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).![EBI](/images/logo_chembl.png) |
Wyeth Research |
19864136 |
45 |
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.![EBI](/images/logo_chembl.png) |
Wyeth Research |
19632115 |
105 |
4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
20005102 |
34 |
2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.![EBI](/images/logo_chembl.png) |
Glaxosmithkline |
19926477 |
100 |
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.![EBI](/images/logo_chembl.png) |
Abbott Laboratories |
19327989 |
40 |
Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.![EBI](/images/logo_chembl.png) |
Pfizer |
18815050 |
34 |
4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.![EBI](/images/logo_chembl.png) |
Wyeth Research |
16931012 |
61 |
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.![EBI](/images/logo_chembl.png) |
Targegen |
15955699 |
33 |
(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.![EBI](/images/logo_chembl.png) |
Glaxosmithkline |
15896957 |
1 |
Structure-activity relationship of N-methyl-bisindolylmaleimide derivatives as cell death inhibitors.![EBI](/images/logo_chembl.png) |
Tohoku University |
32324396 |
17 |
p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.![EBI](/images/logo_chembl.png) |
China Pharmaceutical University |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.![EBI](/images/logo_chembl.png) |
Merck |
27491711 |
422 |
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.![EBI](/images/logo_chembl.png) |
Merck And |
31298542 |
108 |
Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.![EBI](/images/logo_chembl.png) |
Chinese Academy of Sciences |
30986571 |
66 |
Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.![EBI](/images/logo_chembl.png) |
Zhejiang University |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.![EBI](/images/logo_chembl.png) |
University of Florida |
31526603 |
379 |
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.![EBI](/images/logo_chembl.png) |
Takeda Pharmaceutical |
26509640 |
234 |
Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.![EBI](/images/logo_chembl.png) |
Abbvie Bioresearch Center |
23275831 |
121 |
Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).![EBI](/images/logo_chembl.png) |
Moffitt Cancer Center |
30170943 |
35 |
Design and synthesis of potent RSK inhibitors.![EBI](/images/logo_chembl.png) |
Novartis Institutes For Biomedical Research |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
28615111 |
24 |
Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives.![EBI](/images/logo_chembl.png) |
Universit£ |
29655979 |
25 |
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT.![EBI](/images/logo_chembl.png) |
Eli Lilly |
9577836 |
119 |
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.![BDB](/images/logo_bindingdb.png) |
University of Toronto |